Physician profile
Karan Josan
NPI 1124491717
$7,878.63
in general payments reported to CMS, 2019-2025
49 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,256 · 2020: $1,518 · 2021: $2,167 · 2022: $579 · 2023: $209 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $172 · Long Term Medical Supply Or Device Loan: $167 · Education: $19.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $171.77 |
| Long Term Medical Supply Or Device Loan | $166.66 |
| Education | $19.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,748.56 | 2019-2023 | |
| Janssen Biotech, INC. | $690.93 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $411.37 | 2019-2023 | Keytruda |
| Takeda Pharmaceuticals U.S.A., INC. | $398.99 | 2019-2020 | |
| Pfizer INC. | $328.95 | 2019-2021 | |
| Lilly USA, LLC | $320.57 | 2019-2021 | |
| Astellas Pharma US INC | $301.97 | 2019-2020 | |
| Amgen INC. | $301.27 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $279.83 | 2019-2021 | |
| Celgene Corporation | $228.97 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $212.05 | 2019-2021 | |
| Puma Biotechnology, INC. | $190.22 | 2019-2020 | |
| Incyte Corporation | $168.83 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $151.71 | 2021 | |
| Novocure INC. | $148.84 | 2025 | Optune Lua (Novottf-200t) |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karan Josan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.